NRx Pharmaceuticals (NASDAQ:NRXP) Given Buy Rating at D. Boral Capital

Key Points

• NRx Pharmaceuticals has received a "buy" rating from D. Boral Capital with a price target set at $34.00.
• Other analysts have also rated the stock positively, with HC Wainwright setting a price objective of $40.00, while Zacks raised it to a "hold."
• The company reported a quarterly loss of ($0.98) EPS, missing the consensus estimate by ($0.67).

NRx Pharmaceuticals (NASDAQ:NRXP - Get Free Report)'s stock had its "buy" rating reissued by analysts at D. Boral Capital in a research note issued to investors on Thursday,Benzinga reports. They currently have a $34.00 price target on the stock.

Several other equities analysts have also recently weighed in on the company. HC Wainwright initiated coverage on NRx Pharmaceuticals in a report on Monday, September 8th. They issued a "buy" rating and a $40.00 price objective for the company. Zacks Research raised NRx Pharmaceuticals to a "hold" rating in a report on Wednesday, September 10th. Finally, BTIG Research reaffirmed a "buy" rating on shares of NRx Pharmaceuticals in a report on Monday, August 25th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Hold rating to the company's stock. According to MarketBeat.com, NRx Pharmaceuticals currently has a consensus rating of "Buy" and a consensus target price of $34.50.

NRx Pharmaceuticals Trading Up 4.9%

NASDAQ:NRXP opened at $2.99 on Thursday. The stock has a market cap of $59.23 million, a P/E ratio of -1.33 and a beta of 1.63. The stock has a 50 day simple moving average of $2.75 and a 200 day simple moving average of $2.60. NRx Pharmaceuticals has a 1-year low of $1.10 and a 1-year high of $6.01.

NRx Pharmaceuticals (NASDAQ:NRXP - Get Free Report) last released its quarterly earnings results on Monday, August 18th. The company reported ($0.98) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.67). As a group, sell-side analysts forecast that NRx Pharmaceuticals will post -1.75 EPS for the current year.

Hedge Funds Weigh In On NRx Pharmaceuticals

A number of institutional investors have recently modified their holdings of NRXP. Millennium Management LLC acquired a new position in NRx Pharmaceuticals in the 4th quarter worth about $61,000. Squarepoint Ops LLC acquired a new position in NRx Pharmaceuticals in the 4th quarter worth about $56,000. Anson Funds Management LP increased its holdings in NRx Pharmaceuticals by 535.1% in the 1st quarter. Anson Funds Management LP now owns 1,179,061 shares of the company's stock worth $2,417,000 after purchasing an additional 993,401 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in NRx Pharmaceuticals by 27.9% in the 2nd quarter. Geode Capital Management LLC now owns 172,255 shares of the company's stock worth $562,000 after purchasing an additional 37,598 shares in the last quarter. Institutional investors and hedge funds own 4.27% of the company's stock.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.